Cardura XL Approval History
- FDA approved: Yes (First approved February 22nd, 2005)
- Brand name: Cardura XL
- Generic name: doxazosin mesylate
- Dosage form: Extended Release Tablets
- Company: Pfizer Inc.
- Treatment for: Benign Prostatic Hyperplasia
Cardura XL is an extended release formulation providing a controlled release of doxazosin over a 24-hour period. Cardura XL is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Cardura XL is not indicated for the treatment of hypertension.
Development History and FDA Approval Process for Cardura XL
|Feb 22, 2005||Cardura XL Pfizer Inc. - Treatment for Benign Prostatic Hyperplasia (BPH)|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.